CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 25 enrolled
Drug / intervention
Pembrolizumabbiological
Likely dose
Pembrolizumab 200mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02955758
NCT02955758Phase 2Completed
CompareCT.gov

A Phase 2 Trial of Pembrolizumab in Metastatic Non-squamous NSCLC Examining Circulating Tumor DNA Levels as a Surrogate Biomarker of Response

Joel Neal·interventional·Posted Nov 4, 2016·Updated Oct 9, 2024

In Brief

A Phase 2 clinical trial evaluating Pembrolizumab for Metastatic Non-Squamous Non-Small Cell Lung Carcinoma. Completed, enrolled 25 participants across 1 site.

Detailed Summary

This phase II trial studies how well pembrolizumab works in treating patients with non-squamous non-small cell lung cancer which has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Non-Squamous Non-Small Cell Lung Carcinoma
CountriesUnited States
CollaboratorsMerck Sharp & Dohme LLC

Timeline

Phase 2CompletedFinished
2017201820192020202120222023202420252026
First PostedNov 4, 2016
Enrollment StartOct 1, 2016
Primary CompletionApr 9, 2024
TodayJul 2, 2026
Enrollment to primary: 7.5 yearsPosted 9.7 years ago

Interventions

Pembrolizumabbiological

Given IV, 200mg fixed dose, every 3 weeks